Introduction: LIH Department DCR

Here are preliminary results of the bibliometric mapping of the 2022 Luxembourg research evaluation. Its purpose is:

The method for the research-field-mapping can be reviewed here:

Rakas, M., & Hain, D. S. (2019). The state of innovation system research: What happens beneath the surface?. Research Policy, 48(9), 103787.

Seed Articles

The seed articles deemed representative for the active areas of research in the institution, and include authors affiliated with the institution. They can be selected in three ways:

  1. Via bibliographic clustering of the institutions publications and selection of most central articles per cluster (only clsuters where n >= 0.05N). Selection can be found at: https://github.com/daniel-hain/biblio_lux_2022/blob/master/output/seed/scopus_lih_dcr_seed.csv
  2. Manual selection of relevant publications.
  3. A combination of 1. and 2.

The present analysis is based on the following seed articles:

AU PY TI JI
KIWELER N;DELBROUCK C;POZDE… 2022 MITOCHONDRIA PRESERVE AN AUTARKIC ONE-CARBON CYCLE TO CONFER GROWTH-INDEPENDENT CANCER CELL MIGRA… NAT. COMMUN.
SHARMA AB;ERASIMUS H;PINTO … 2021 XAB2 PROMOTES KU EVICTION FROM SINGLE-ENDED DNA DOUBLE-STRAND BREAKS INDEPENDENTLY OF THE ATM KINASE NUCLEIC ACIDS RES.
GOLEBIEWSKA A;HAU A-C;OUDIN… 2020 PATIENT-DERIVED ORGANOIDS AND ORTHOTOPIC XENOGRAFTS OF PRIMARY AND RECURRENT GLIOMAS REPRESENT RE… ACTA NEUROPATHOL.
NOMAN MZ;PARPAL S;VAN MOER … 2020 INHIBITION OF VPS34 REPROGRAMS COLD INTO HOT INFLAMED TUMORS AND IMPROVES ANTI-PD-1/PD-L1 IMMUNOT… SCI. ADV.
WIERZ M;PIERSON S;GUYONNET … 2018 DUAL PD1/LAG3 IMMUNE CHECKPOINT BLOCKADE LIMITS TUMOR DEVELOPMENT IN A MURINE MODEL OF CHRONIC LY… BLOOD

Topic modelling

Here, we report the results of a LDA topic-modelling (basically, clustering on words) on all title+abstract texts.

Topics by topwords

Note: While this static vies is helpful, I recommend using the interactive LDAVis version to be found under https://daniel-hain.github.io/biblio_lux_2022/output/topic_modelling/LDAviz_lih_dcr.rds/index.html#topic=1&lambda=0.60&term=. For functionality and usage, see technical description in the next tab.

Topics over time

Technical Description

LDA Topic Modelling

Topic modeling is a type of statistical modeling for discovering the abstract “topics” that occur in a collection of documents. Latent Dirichlet Allocation (LDA, Blei et al., 2003) is an example of topic model and is used to classify text in a document to a particular topic.

LDA is a generative probabilistic model that assumes each topic is a mixture over an underlying set of words, and each document is a mixture of over a set of topic probabilities. It builds a topic per document model and words per topic model, modeled as Dirichlet distributions.

LDAVis

LDAvis is a web-based interactive visualisation of topics estimated using LDA (Sievert & Shirley, 2014). It provides a global view of the topics (and how they differ from each other), while at the same time allowing for a deep inspection of the terms most highly associated with each individual topic. The package extracts information from a fitted LDA topic model to inform an interactive web-based visualization. The visualisation has two basic pieces.

The left panel visualise the topics as circles in the two-dimensional plane whose centres are determined by computing the Jensen–Shannon divergence between topics, and then by using multidimensional scaling to project the inter-topic distances onto two dimensions. Each topic’s overall prevalence is encoded using the areas of the circles.

The right panel depicts a horizontal bar chart whose bars represent the individual terms that are the most useful for interpreting the currently selected topic on the left. A pair of overlaid bars represent both the corpus-wide frequency of a given term as well as the topic-specific frequency of the term.

The \(\lambda\) slider allows to rank the terms according to term relevance. By default, the terms of a topic are ranked in decreasing order according their topic-specific probability ( \(\lambda\) = 1 ). Moving the slider allows to adjust the rank of terms based on much discriminatory (or “relevant”) are for the specific topic. The suggested optimal value of \(\lambda\) is 0.6.

Knowledge Bases: Co-Citation network analysis

Note: This analysis refers the co-citation analysis, where the cited references and not the original publications are the unit of analysis. See tab Technical descriptionfor additional explanations

Knowledge Bases summary

In order to partition networks into components or clusters, we deploy a community detection technique based on the Lovain Algorithm (Blondel et al., 2008). The Lovain Algorithm is a heuristic method that attempts to optimize the modularity of communities within a network by maximizing within- and minimizing between-community connectivity. We identify the following communities = knowledge bases.

name dgr_int dgr
Knowledge Base 1: KB 1: unlabeled (n = 2403, density =2.82)
PARDOLL D.M. THE BLOCKADE OF IMMUNE CHECKPOINTS IN CANCER IMMUNOTHERAPY (2012) 9566 9783
POSTOW M.A. CALLAHAN M.K. WOLCHOK J.D. IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPY (2015) 4377 4419
TOPALIAN S.L. HODI F.S. BRAHMER J.R. SAFETY ACTIVITY AND IMMUNE CORRELATES OF ANTI-PD-1 ANTIBODY IN CANCER (2012) 2312 2360
TUMEH P.C. HARVIEW C.L. YEARLEY J.H. PD-1 BLOCKADE INDUCES RESPONSES BY INHIBITING ADAPTIVE IMMUNE RESISTANCE (2014) 2199 2234
TUMEH P.C. HARVIEW C.L. YEARLEY J.H. SHINTAKU I.P. TAYLOR E.J. ROBERT L. PD-1 BLOCKADE INDUCES RESPONSES BY INHIBITING ADAPTIVE IMMUNE RESISTANCE (… 1919 1980
TOPALIAN S.L. TAUBE J.M. ANDERS R.A. PARDOLL D.M. MECHANISM-DRIVEN BIOMARKERS TO GUIDE IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPY (2016) 1767 1829
BORGHAEI H. PAZ-ARES L. HORN L. NIVOLUMAB VERSUS DOCETAXEL IN ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER (2015) 1736 1750
SHARMA P. ALLISON J.P. THE FUTURE OF IMMUNE CHECKPOINT THERAPY (2015) 1710 1739
BRAHMER J. RECKAMP K.L. BAAS P. NIVOLUMAB VERSUS DOCETAXEL IN ADVANCED SQUAMOUS-CELL NON-SMALL-CELL LUNG CANCER (2015) 1672 1700
TOPALIAN S.L. DRAKE C.G. PARDOLL D.M. IMMUNE CHECKPOINT BLOCKADE: A COMMON DENOMINATOR APPROACH TO CANCER THERAPY (2015) 1487 1511
Knowledge Base 2: KB 2: unlabeled (n = 1998, density =4.04)
LOCASALE J.W. SERINE GLYCINE AND ONE-CARBON UNITS: CANCER METABOLISM IN FULL CIRCLE (2013) 3951 4020
HANAHAN D. WEINBERG R.A. HALLMARKS OF CANCER: THE NEXT GENERATION (2011) 3505 6831
VANDER HEIDEN M.G. CANTLEY L.C. THOMPSON C.B. UNDERSTANDING THE WARBURG EFFECT: THE METABOLIC REQUIREMENTS OF CELL PROLIFERATION (2009) 3357 3742
WARBURG O. ON THE ORIGIN OF CANCER CELLS (1956) 2843 3008
PAVLOVA N.N. THOMPSON C.B. THE EMERGING HALLMARKS OF CANCER METABOLISM (2016) 2809 3059
FAN J. YE J. KAMPHORST J.J. SHLOMI T. THOMPSON C.B. RABINOWITZ J.D. QUANTITATIVE FLUX ANALYSIS REVEALS FOLATE-DEPENDENT NADPH PRODUCTION (2014) 2495 2514
POSSEMATO R. MARKS K.M. SHAUL Y.D. PACOLD M.E. KIM D. BIRSOY K. SETHUMADHAVAN S. JHA A.K. FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATH… 2312 2363
PISKOUNOVA E. AGATHOCLEOUS M. MURPHY M.M. HU Z. HUDDLESTUN S.E. ZHAO Z. LEITCH A.M. MORRISON S.J. OXIDATIVE STRESS INHIBITS DISTANT METASTASIS BY H… 2067 2085
LOCASALE J.W. GRASSIAN A.R. MELMAN T. LYSSIOTIS C.A. MATTAINI K.R. BASS A.J. HEFFRON G. SHARFI H. PHOSPHOGLYCERATE DEHYDROGENASE DIVERTS GLYCOLYTIC… 2021 2049
SULLIVAN L.B. GUI D.Y. HOSIOS A.M. BUSH L.N. FREINKMAN E. VANDER HEIDEN M.G. SUPPORTING ASPARTATE BIOSYNTHESIS IS AN ESSENTIAL FUNCTION OF RESPIRAT… 1711 1733
Knowledge Base 3: KB 3: unlabeled (n = 1743, density =4.4)
CICCIA A. ELLEDGE S.J. THE DNA DAMAGE RESPONSE: MAKING IT SAFE TO PLAY WITH KNIVES (2010) 2610 4267
JACKSON S.P. BARTEK J. THE DNA-DAMAGE RESPONSE IN HUMAN BIOLOGY AND DISEASE (2009) 2175 2792
MIMITOU E.P. SYMINGTON L.S. SAE2 EXO1 AND SGS1 COLLABORATE IN DNA DOUBLE-STRAND BREAK PROCESSING (2008) 2031 2283
SYMINGTON L.S. GAUTIER J. DOUBLE-STRAND BREAK END RESECTION AND REPAIR PATHWAY CHOICE (2011) 1861 2221
SARTORI A.A. LUKAS C. COATES J. MISTRIK M. FU S. BARTEK J. BAER R. JACKSON S.P. HUMAN CTIP PROMOTES DNA END RESECTION (2007) 1773 2149
HUERTAS P. JACKSON S.P. HUMAN CTIP MEDIATES CELL CYCLE CONTROL OF DNA END RESECTION AND DOUBLE STRAND BREAK REPAIR (2009) 1668 1768
CANNAVO E. CEJKA P. SAE2 PROMOTES DSDNA ENDONUCLEASE ACTIVITY WITHIN MRE11-RAD50-XRS2 TO RESECT DNA BREAKS (2014) 1652 1809
ZHU Z. CHUNG W.H. SHIM E.Y. LEE S.E. IRA G. SGS1 HELICASE AND TWO NUCLEASES DNA2 AND EXO1 RESECT DNA DOUBLE-STRAND BREAK ENDS (2008) 1648 1904
CHANG H.H.Y. PANNUNZIO N.R. ADACHI N. LIEBER M.R. NON-HOMOLOGOUS DNA END JOINING AND ALTERNATIVE PATHWAYS TO DOUBLE-STRAND BREAK REPAIR (2017) 1483 1747
JENSEN R.B. CARREIRA A. KOWALCZYKOWSKI S.C. PURIFIED HUMAN BRCA2 STIMULATES RAD51-MEDIATED RECOMBINATION (2010) 1355 2054
Knowledge Base 4: KB 4: unlabeled (n = 1692, density =3.15)
VERHAAK R.G. HOADLEY K.A. PURDOM E. WANG V. QI Y. WILKERSON M.D. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVANT SUBTYPES OF GLIOBLASTOM… 2082 2174
COMPREHENSIVE GENOMIC CHARACTERIZATION DEFINES HUMAN GLIOBLASTOMA GENES AND CORE PATHWAYS (2008) 1731 3063
LOUIS D.N. PERRY A. REIFENBERGER G. VON DEIMLING A. FIGARELLA-BRANGER D. CAVENEE W.K. THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS O… 1693 1790
PATEL A.P. TIROSH I. TROMBETTA J.J. SHALEK A.K. GILLESPIE S.M. WAKIMOTO H. CAHILL D.P. MARTUZA R.L. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HET… 1669 1822
STUPP R. MASON W.P. VAN DEN BENT M.J. WELLER M. FISHER B. TAPHOORN M.J. RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA (2… 1660 1742
LOUIS D.N. PERRY A. REIFENBERGER G. VON DEIMLING A. FIGARELLA-BRANGER D. CAVENEE W.K. OHGAKI H. ELLISON D.W. THE 2016 WORLD HEALTH ORGANIZATION CLA… 1627 1798
BRENNAN C.W. VERHAAK R.G. MCKENNA A. CAMPOS B. NOUSHMEHR H. SALAMA S.R. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) 1599 1659
VERHAAK R.G. HOADLEY K.A. PURDOM E. WANG V. QI Y. WILKERSON M.D. MILLER C.R. MESIROV J.P. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVAN… 1425 1495
PATEL A.P. TIROSH I. TROMBETTA J.J. SHALEK A.K. GILLESPIE S.M. WAKIMOTO H. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HETEROGENEITY IN PRIMARY GLI… 1363 1433
CECCARELLI M. BARTHEL F.P. MALTA T.M. SABEDOT T.S. SALAMA S.R. MURRAY B.A. MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS O… 1295 1367
Knowledge Base 5: KB 5: unlabeled (n = 1555, density =4.48)
ZEMAN M.K. CIMPRICH K.A. CAUSES AND CONSEQUENCES OF REPLICATION STRESS (2014) 3759 5050
ZOU L. ELLEDGE S.J. SENSING DNA DAMAGE THROUGH ATRIP RECOGNITION OF RPA-SSDNA COMPLEXES (2003) 2551 4033
BHOWMICK R. MINOCHERHOMJI S. HICKSON I.D. RAD52 FACILITATES MITOTIC DNA SYNTHESIS FOLLOWING REPLICATION STRESS (2016) 2442 3424
PETERMANN E. ORTA M.L. ISSAEVA N. SCHULTZ N. HELLEDAY T. HYDROXYUREA-STALLED REPLICATION FORKS BECOME PROGRESSIVELY INACTIVATED AND REQUIRE TWO DIF… 2218 2730
SCHLACHER K. CHRIST N. SIAUD N. EGASHIRA A. WU H. JASIN M. DOUBLE-STRAND BREAK REPAIR-INDEPENDENT ROLE FOR BRCA2 IN BLOCKING STALLED REPLICATION FO… 2109 3056
SCHLACHER K. WU H. JASIN M. A DISTINCT REPLICATION FORK PROTECTION PATHWAY CONNECTS FANCONI ANEMIA TUMOR SUPPRESSORS TO RAD51-BRCA1/2 (2012) 1971 2719
NEELSEN K.J. LOPES M. REPLICATION FORK REVERSAL IN EUKARYOTES: FROM DEAD END TO DYNAMIC RESPONSE (2015) 1761 2043
CIMPRICH K.A. CORTEZ D. ATR: AN ESSENTIAL REGULATOR OF GENOME INTEGRITY (2008) 1713 2293
ZELLWEGER R. DALCHER D. MUTREJA K. BERTI M. SCHMID J.A. HERRADOR R. VINDIGNI A. LOPES M. RAD51-MEDIATED REPLICATION FORK REVERSAL IS A GLOBAL RESPO… 1511 1883
HASHIMOTO Y. RAY CHAUDHURI A. LOPES M. COSTANZO V. RAD51 PROTECTS NASCENT DNA FROM MRE11-DEPENDENT DEGRADATION AND PROMOTES CONTINUOUS DNA SYNTHESI… 1137 1334
Knowledge Base 6: KB 6: unlabeled (n = 1337, density =5.71)
MIZUSHIMA N. KOMATSU M. AUTOPHAGY: RENOVATION OF CELLS AND TISSUES (2011) 2064 2080
WHITE E. THE ROLE FOR AUTOPHAGY IN CANCER (2015) 1629 1738
STROHECKER A.M. GUO J.Y. KARSLI-UZUNBAS G. PRICE S.M. CHEN G.J. MATHEW R. MCMAHON M. WHITE E. AUTOPHAGY SUSTAINS MITOCHONDRIAL GLUTAMINE METABOLISM… 1516 1580
YUE Z. JIN S. YANG C. LEVINE A.J. HEINTZ N. BECLIN 1 AN AUTOPHAGY GENE ESSENTIAL FOR EARLY EMBRYONIC DEVELOPMENT IS A HAPLOINSUFFICIENT TUMOR SUPPR… 1470 1490
LEVY J.M.M. TOWERS C.G. THORBURN A. TARGETING AUTOPHAGY IN CANCER (2017) 1464 1486
WEI H. WEI S. GAN B. PENG X. ZOU W. GUAN J.L. SUPPRESSION OF AUTOPHAGY BY FIP200 DELETION INHIBITS MAMMARY TUMORIGENESIS (2011) 1263 1296
WHITE E. DECONVOLUTING THE CONTEXT-DEPENDENT ROLE FOR AUTOPHAGY IN CANCER (2012) 1159 1229
YANG A. RAJESHKUMAR N.V. WANG X. YABUUCHI S. ALEXANDER B.M. CHU G.C. VON HOFF D.D. KIMMELMAN A.C. AUTOPHAGY IS CRITICAL FOR PANCREATIC TUMOR GROWTH… 1140 1217
AMARAVADI R. KIMMELMAN A.C. WHITE E. RECENT INSIGHTS INTO THE FUNCTION OF AUTOPHAGY IN CANCER (2016) 1130 1158
LOCK R. KENIFIC C.M. LEIDAL A.M. SALAS E. DEBNATH J. AUTOPHAGY-DEPENDENT PRODUCTION OF SECRETED FACTORS FACILITATES ONCOGENIC RAS-DRIVEN INVASION (… 1118 1130
Knowledge Base 7: KB 7: unlabeled (n = 708, density =6.27)
BRENNAN C.W. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) 1413 1530
PATEL A.P. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HETEROGENEITY IN PRIMARY GLIOBLASTOMA (2014) 1140 1223
VERHAAK R.G. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVANT SUBTYPES OF GLIOBLASTOMA CHARACTERIZED BY ABNORMALITIES IN PDGFRA IDH1 EGFR… 795 871
STUPP R. RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA (2005) 677 737
CECCARELLI M. MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS OF PROGRESSION IN DIFFUSE GLIOMA (2016) 675 708
LOVE M.I. HUBER W. ANDERS S. MODERATED ESTIMATION OF FOLD CHANGE AND DISPERSION FOR RNA-SEQ DATA WITH DESEQ2 (2014) 561 877
BUTLER A. HOFFMAN P. SMIBERT P. PAPALEXI E. SATIJA R. INTEGRATING SINGLE-CELL TRANSCRIPTOMIC DATA ACROSS DIFFERENT CONDITIONS TECHNOLOGIES AND SPEC… 558 659
WANG Q. TUMOR EVOLUTION OF GLIOMA-INTRINSIC GENE EXPRESSION SUBTYPES ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT (2017) 537 580
LOUIS D.N. THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM: A SUMMARY (2016) 508 531
DOBIN A. STAR: ULTRAFAST UNIVERSAL RNA-SEQ ALIGNER (2013) 508 539
Knowledge Base 8: KB 8: unlabeled (n = 653, density =9.97)
STUPP R. MASON W.P. VAN DEN BENT M.J. RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA (2005) 2127 2286
LOUIS D.N. PERRY A. REIFENBERGER G. THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM: A SUMMARY (2016) 2075 2191
HEGI M.E. DISERENS A.C. GORLIA T. MGMT GENE SILENCING AND BENEFIT FROM TEMOZOLOMIDE IN GLIOBLASTOMA (2005) 1487 1537
YAN H. PARSONS D.W. JIN G. IDH1 AND IDH2 MUTATIONS IN GLIOMAS (2009) 1464 1557
BRENNAN C.W. VERHAAK R.G. MCKENNA A. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) 1163 1239
PARSONS D.W. JONES S. ZHANG X. AN INTEGRATED GENOMIC ANALYSIS OF HUMAN GLIOBLASTOMA MULTIFORME (2008) 1070 1121
PATEL A.P. TIROSH I. TROMBETTA J.J. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HETEROGENEITY IN PRIMARY GLIOBLASTOMA (2014) 1045 1096
VERHAAK R.G. HOADLEY K.A. PURDOM E. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVANT SUBTYPES OF GLIOBLASTOMA CHARACTERIZED BY ABNORMALIT… 926 997
CECCARELLI M. BARTHEL F.P. MALTA T.M. MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS OF PROGRESSION IN DIFFUSE GLIOMA (2016) 822 864
STUPP R. HEGI M.E. MASON W.P. EFFECTS OF RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE VERSUS RADIOTHERAPY ALONE ON SURVIVAL IN GLIOBLAST… 775 818

Development of Knowledge Bases

Technical description

In a co-cittion network, the strength of the relationship between a reference pair \(m\) and \(n\) (\(s_{m,n}^{coc}\)) is expressed by the number of publications \(C\) which are jointly citing reference \(m\) and \(n\).

\[s_{m,n}^{coc} = \sum_i c_{i,m} c_{i,n}\]

The intuition here is that references which are frequently cited together are likely to share commonalities in theory, topic, methodology, or context. It can be interpreted as a measure of similarity as evaluated by other researchers that decide to jointly cite both references. Because the publication process is time-consuming, co-citation is a backward-looking measure, which is appropriate to map the relationship between core literature of a field.

Research Areas: Bibliographic coupling analysis

Research Areas main summary

This is arguably the more interesting part. Here, we identify the literature’s current knowledge frontier by carrying out a bibliographic coupling analysis of the publications in our corpus. This measure uses bibliographical information of publications to establish a similarity relationship between them. Again, method details to be found in the tab Technical description. As you will see, we identify the main research area, but also a set of adjacent research areas with some theoretical/methodological/application overlap.

To identify communities in the field’s knowledge frontier (labeled research areas) we again use the Lovain Algorithm (Blondel et al., 2008). We identify the following communities = research areas.

label AU PY TI dgr_int TC TC_year
Research Area 1: RA 1: unlabeled (n = 993, density =0.28)
RA 1: unlabeled CHEN DS;MELLMAN I 2017 ELEMENTS OF CANCER IMMUNITY AND THE CANCER-IMMUNE SET POINT 6.94 2201 440.20
RA 1: unlabeled ANTONIA SJ;VILLEGAS A;… 2017 DURVALUMAB AFTER CHEMORADIOTHERAPY IN STAGE III NON–SMALL-CELL LUNG CANCER 5.03 2218 443.60
RA 1: unlabeled AYERS M;LUNCEFORD J;NE… 2017 IFN-Γ-RELATED MRNA PROFILE PREDICTS CLINICAL RESPONSE TO PD-1 BLOCKADE 6.42 1478 295.60
RA 1: unlabeled ALSAAB HO;SAU S;ALZHRA… 2017 PD-1 AND PD-L1 CHECKPOINT SIGNALING INHIBITION FOR CANCER IMMUNOTHERAPY: MECHANISM, COMBINATIONS, AND CLINICAL OUTCOME 10.65 834 166.80
RA 1: unlabeled RIBAS A;DUMMER R;PUZAN… 2017 ONCOLYTIC VIROTHERAPY PROMOTES INTRATUMORAL T CELL INFILTRATION AND IMPROVES ANTI-PD-1 IMMUNOTHERAPY 10.03 779 155.80
RA 1: unlabeled MARIATHASAN S;TURLEY S… 2018 TGFΒ ATTENUATES TUMOUR RESPONSE TO PD-L1 BLOCKADE BY CONTRIBUTING TO EXCLUSION OF T CELLS 3.07 1761 440.25
RA 1: unlabeled SKOULIDIS F;GOLDBERG M… 2018 STK11/LKB1 MUTATIONS AND PD-1 INHIBITOR RESISTANCE IN KRAS-MUTANT LUNG ADENOCARCINOMA 5.90 663 165.75
RA 1: unlabeled RIAZ N;HAVEL JJ;MAKARO… 2017 TUMOR AND MICROENVIRONMENT EVOLUTION DURING IMMUNOTHERAPY WITH NIVOLUMAB 4.11 825 165.00
RA 1: unlabeled DONG Z-Y;ZHONG W-Z;ZHA… 2017 POTENTIAL PREDICTIVE VALUE OF TP53 AND KRAS MUTATION STATUS FOR RESPONSE TO PD-1 BLOCKADE IMMUNOTHERAPY IN LUNG ADENOCARCI… 7.16 465 93.00
RA 1: unlabeled HUANG AC;POSTOW MA;ORL… 2017 T-CELL INVIGORATION TO TUMOUR BURDEN RATIO ASSOCIATED WITH ANTI-PD-1 RESPONSE 3.56 863 172.60
Research Area 2: RA 2: unlabeled (n = 932, density =0.3)
RA 2: unlabeled BLACKFORD AN;JACKSON SP 2017 ATM, ATR, AND DNA-PK: THE TRINITY AT THE HEART OF THE DNA DAMAGE RESPONSE 5.25 792 158.40
RA 2: unlabeled SCULLY R;PANDAY A;ELAN… 2019 DNA DOUBLE-STRAND BREAK REPAIR-PATHWAY CHOICE IN SOMATIC MAMMALIAN CELLS 9.35 397 132.33
RA 2: unlabeled SALDIVAR JC;CORTEZ D;C… 2017 THE ESSENTIAL KINASE ATR: ENSURING FAITHFUL DUPLICATION OF A CHALLENGING GENOME 5.88 342 68.40
RA 2: unlabeled CECCALDI R;RONDINELLI … 2016 REPAIR PATHWAY CHOICES AND CONSEQUENCES AT THE DOUBLE-STRAND BREAK 2.46 768 128.00
RA 2: unlabeled BHOWMICK R;MINOCHERHOM… 2016 RAD52 FACILITATES MITOTIC DNA SYNTHESIS FOLLOWING REPLICATION STRESS 6.71 198 33.00
RA 2: unlabeled SOTIRIOU SK;KAMILERI I… 2016 MAMMALIAN RAD52 FUNCTIONS IN BREAK-INDUCED REPLICATION REPAIR OF COLLAPSED DNA REPLICATION FORKS 7.31 166 27.67
RA 2: unlabeled RANJHA L;HOWARD SM;CEJ… 2018 MAIN STEPS IN DNA DOUBLE-STRAND BREAK REPAIR: AN INTRODUCTION TO HOMOLOGOUS RECOMBINATION AND RELATED PROCESSES 7.67 148 37.00
RA 2: unlabeled LEMAÇON D;JACKSON J;QU… 2017 MRE11 AND EXO1 NUCLEASES DEGRADE REVERSED FORKS AND ELICIT MUS81-DEPENDENT FORK RESCUE IN BRCA2-DEFICIENT CELLS 6.28 180 36.00
RA 2: unlabeled ANAND R;RANJHA L;CANNA… 2016 PHOSPHORYLATED CTIP FUNCTIONS AS A CO-FACTOR OF THE MRE11-RAD50-NBS1 ENDONUCLEASE IN DNA END RESECTION 6.81 164 27.33
RA 2: unlabeled BERTI M;VINDIGNI A 2016 REPLICATION STRESS: GETTING BACK ON TRACK 7.07 151 25.17
Research Area 3: RA 3: unlabeled (n = 819, density =0.3)
RA 3: unlabeled PAVLOVA NN;THOMPSON CB 2016 THE EMERGING HALLMARKS OF CANCER METABOLISM 5.17 2546 424.33
RA 3: unlabeled DE BERARDINIS RJ;CHAND… 2016 FUNDAMENTALS OF CANCER METABOLISM 6.70 1281 213.50
RA 3: unlabeled VANDER HEIDEN MG;DEBER… 2017 UNDERSTANDING THE INTERSECTIONS BETWEEN METABOLISM AND CANCER BIOLOGY 7.27 981 196.20
RA 3: unlabeled DUCKER GS;RABINOWITZ JD 2017 ONE-CARBON METABOLISM IN HEALTH AND DISEASE 6.81 738 147.60
RA 3: unlabeled VYAS S;ZAGANJOR E;HAIG… 2016 MITOCHONDRIA AND CANCER 5.74 813 135.50
RA 3: unlabeled ZONG W-X;RABINOWITZ JD… 2016 MITOCHONDRIA AND CANCER 6.44 518 86.33
RA 3: unlabeled ALTMAN BJ;STINE ZE;DAN… 2016 FROM KREBS TO CLINIC: GLUTAMINE METABOLISM TO CANCER THERAPY 2.96 917 152.83
RA 3: unlabeled LUENGO A;GUI DY;VANDER… 2017 TARGETING METABOLISM FOR CANCER THERAPY 6.59 403 80.60
RA 3: unlabeled YANG M;VOUSDEN KH 2016 SERINE AND ONE-CARBON METABOLISM IN CANCER 5.84 433 72.17
RA 3: unlabeled PANIERI E;SANTORO MM 2016 ROS HOMEOSTASIS AND METABOLISM: A DANGEROUS LIASON IN CANCER CELLS 3.69 629 104.83
Research Area 4: RA 4: unlabeled (n = 559, density =0.26)
RA 4: unlabeled CECCARELLI M;BARTHEL F… 2016 MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS OF PROGRESSION IN DIFFUSE GLIOMA 3.82 1127 187.83
RA 4: unlabeled WANG Q;HU B;HU X;KIM H… 2017 TUMOR EVOLUTION OF GLIOMA-INTRINSIC GENE EXPRESSION SUBTYPES ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT 5.07 671 134.20
RA 4: unlabeled NEFTEL C;LAFFY J;FILBI… 2019 AN INTEGRATIVE MODEL OF CELLULAR STATES, PLASTICITY, AND GENETICS FOR GLIOBLASTOMA 5.05 562 187.33
RA 4: unlabeled COLAPRICO A;SILVA TC;O… 2016 TCGABIOLINKS: AN R/BIOCONDUCTOR PACKAGE FOR INTEGRATIVE ANALYSIS OF TCGA DATA 1.69 1182 197.00
RA 4: unlabeled JACOB F;SALINAS RD;ZHA… 2020 A PATIENT-DERIVED GLIOBLASTOMA ORGANOID MODEL AND BIOBANK RECAPITULATES INTER- AND INTRA-TUMORAL HETEROGENEITY 4.15 246 123.00
RA 4: unlabeled SEGERMAN A;NIKLASSON M… 2016 CLONAL VARIATION IN DRUG AND RADIATION RESPONSE AMONG GLIOMA-INITIATING CELLS IS LINKED TO PRONEURAL-MESENCHYMAL TRANSITION 5.99 108 18.00
RA 4: unlabeled MALTA TM;SOKOLOV A;GEN… 2018 MACHINE LEARNING IDENTIFIES STEMNESS FEATURES ASSOCIATED WITH ONCOGENIC DEDIFFERENTIATION 1.12 558 139.50
RA 4: unlabeled HU B;WANG Q;WANG YA;HU… 2016 EPIGENETIC ACTIVATION OF WNT5A DRIVES GLIOBLASTOMA STEM CELL DIFFERENTIATION AND INVASIVE GROWTH 3.55 151 25.17
RA 4: unlabeled LENTING K;VERHAAK R;TE… 2017 GLIOMA: EXPERIMENTAL MODELS AND REALITY 3.26 163 32.60
RA 4: unlabeled LIAU BB;SIEVERS C;DONO… 2017 ADAPTIVE CHROMATIN REMODELING DRIVES GLIOBLASTOMA STEM CELL PLASTICITY AND DRUG TOLERANCE 2.25 231 46.20
Research Area 5: RA 5: unlabeled (n = 446, density =0.56)
RA 5: unlabeled BEHNAN J;FINOCCHIARO G… 2019 THE LANDSCAPE OF THE MESENCHYMAL SIGNATURE IN BRAIN TUMOURS 9.09 123 41.00
RA 5: unlabeled CHEN Z;HAMBARDZUMYAN D 2018 IMMUNE MICROENVIRONMENT IN GLIOBLASTOMA SUBTYPES 4.98 167 41.75
RA 5: unlabeled PATEL SH;POISSON LM;BR… 2017 T2–FLAIR MISMATCH, AN IMAGING BIOMARKER FOR IDH AND 1P/19Q STATUS IN LOWER-GRADE GLIOMAS: A TCGA/TCIA PROJECT 5.05 153 30.60
RA 5: unlabeled JOHANNS TM;MILLER CA;D… 2016 IMMUNOGENOMICS OF HYPERMUTATED GLIOBLASTOMA: A PATIENT WITH GERMLINE POLE DEFICIENCY TREATED WITH CHECKPOINT BLOCKADE IMMU… 3.35 202 33.67
RA 5: unlabeled DANIEL P;SABRI S;CHADD… 2019 TEMOZOLOMIDE INDUCED HYPERMUTATION IN GLIOMA: EVOLUTIONARY MECHANISMS AND THERAPEUTIC OPPORTUNITIES 7.59 86 28.67
RA 5: unlabeled AN Z;AKSOY O;ZHENG T;F… 2018 EPIDERMAL GROWTH FACTOR RECEPTOR AND EGFRVIII IN GLIOBLASTOMA: SIGNALING PATHWAYS AND TARGETED THERAPIES 3.21 200 50.00
RA 5: unlabeled ZHANG C;CHENG W;REN X;… 2017 TUMOR PURITY AS AN UNDERLYING KEY FACTOR IN GLIOMA 3.24 177 35.40
RA 5: unlabeled ZHAO Z;ZHANG K-N;WANG … 2021 CHINESE GLIOMA GENOME ATLAS (CGGA): A COMPREHENSIVE RESOURCE WITH FUNCTIONAL GENOMIC DATA FROM CHINESE GLIOMA PATIENTS 3.91 107 107.00
RA 5: unlabeled JONSSON P;LIN AL;YOUNG… 2019 GENOMIC CORRELATES OF DISEASE PROGRESSION AND TREATMENT RESPONSE IN PROSPECTIVELY CHARACTERIZED GLIOMAS 6.93 54 18.00
RA 5: unlabeled KARSY M;GUAN J;COHEN A… 2017 NEW MOLECULAR CONSIDERATIONS FOR GLIOMA: IDH, ATRX, BRAF, TERT, H3 K27M 4.99 69 13.80
Research Area 6: RA 6: unlabeled (n = 445, density =0.9)
RA 6: unlabeled BUCHBINDER EI;DESAI A 2016 CTLA-4 AND PD-1 PATHWAYS SIMILARITIES, DIFFERENCES, AND IMPLICATIONS OF THEIR INHIBITION 10.43 1093 182.17
RA 6: unlabeled HORN L;SPIGEL DR;VOKES… 2017 NIVOLUMAB VERSUS DOCETAXEL IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: TWO-YEAR OUTCOMES FROM… 8.81 512 102.40
RA 6: unlabeled LESOKHIN AM;ANSELL SM;… 2016 NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCY: PRELIMINARY RESULTS OF A PHASE IB STUDY 5.93 674 112.33
RA 6: unlabeled RIBAS A;HAMID O;DAUD A… 2016 ASSOCIATION OF PEMBROLIZUMAB WITH TUMOR RESPONSE AND SURVIVAL AMONG PATIENTS WITH ADVANCED MELANOMA 5.37 696 116.00
RA 6: unlabeled MASSARD C;GORDON MS;SH… 2016 SAFETY AND EFFICACY OF DURVALUMAB (MEDI4736), AN ANTI-PROGRAMMED CELL DEATH LIGAND-1 IMMUNE CHECKPOINT INHIBITOR, IN PATIE… 5.98 622 103.67
RA 6: unlabeled ARMAND P;SHIPP MA;RIBR… 2016 PROGRAMMED DEATH-1 BLOCKADE WITH PEMBROLIZUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE 6.43 481 80.17
RA 6: unlabeled GARASSINO MC;CHO B-C;K… 2018 DURVALUMAB AS THIRD-LINE OR LATER TREATMENT FOR ADVANCED NON-SMALL-CELL LUNG CANCER (ATLANTIC): AN OPEN-LABEL, SINGLE-ARM,… 8.67 336 84.00
RA 6: unlabeled D’ANGELO SP;MAHONEY MR… 2018 NIVOLUMAB WITH OR WITHOUT IPILIMUMAB TREATMENT FOR METASTATIC SARCOMA (ALLIANCE A091401): TWO OPEN-LABEL, NON-COMPARATIVE,… 7.57 301 75.25
RA 6: unlabeled ETTINGER DS;WOOD DE;AK… 2016 NCCN GUIDELINES® INSIGHTS: NON-SMALL CELL LUNG CANCER, VERSION 4.2016 FEATURED UPDATES TO THE NCCN GUIDELINES 7.43 302 50.33
RA 6: unlabeled BALAR AV;CASTELLANO D;… 2017 FIRST-LINE PEMBROLIZUMAB IN CISPLATIN-INELIGIBLE PATIENTS WITH LOCALLY ADVANCED AND UNRESECTABLE OR METASTATIC UROTHELIAL … 2.80 704 140.80
Research Area 7: RA 7: unlabeled (n = 396, density =0.35)
RA 7: unlabeled LEVY JMM;TOWERS CG;THO… 2017 TARGETING AUTOPHAGY IN CANCER 2.74 1218 243.60
RA 7: unlabeled KIMMELMAN AC;WHITE E 2017 AUTOPHAGY AND TUMOR METABOLISM 5.81 454 90.80
RA 7: unlabeled AMARAVADI R;KIMMELMAN … 2016 RECENT INSIGHTS INTO THE FUNCTION OF AUTOPHAGY IN CANCER 5.50 462 77.00
RA 7: unlabeled DIKIC I;ELAZAR Z 2018 MECHANISM AND MEDICAL IMPLICATIONS OF MAMMALIAN AUTOPHAGY 1.90 1130 282.50
RA 7: unlabeled AMARAVADI RK;KIMMELMAN… 2019 TARGETING AUTOPHAGY IN CANCER: RECENT ADVANCES AND FUTURE DIRECTIONS 3.09 310 103.33
RA 7: unlabeled GUO JY;TENG X;LADDHA S… 2016 AUTOPHAGY PROVIDES METABOLIC SUBSTRATES TO MAINTAIN ENERGY CHARGE AND NUCLEOTIDE POOLS IN RAS-DRIVEN LUNG CANCER CELLS 3.37 217 36.17
RA 7: unlabeled WHITE E 2016 AUTOPHAGY AND P53 4.14 171 28.50
RA 7: unlabeled MOWERS EE;SHARIFI MN;M… 2017 AUTOPHAGY IN CANCER METASTASIS 2.45 286 57.20
RA 7: unlabeled ONORATI AV;DYCZYNSKI M… 2018 TARGETING AUTOPHAGY IN CANCER 2.31 277 69.25
RA 7: unlabeled SHARIFI MN;MOWERS EE;D… 2016 AUTOPHAGY PROMOTES FOCAL ADHESION DISASSEMBLY AND CELL MOTILITY OF METASTATIC TUMOR CELLS THROUGH THE DIRECT INTERACTION O… 3.37 183 30.50
Research Area 8: RA 8: unlabeled (n = 395, density =0.95)
RA 8: unlabeled STUPP R;TAILLIBERT S;K… 2017 EFFECT OF TUMOR-TREATING FIELDS PLUS MAINTENANCE TEMOZOLOMIDE VS MAINTENANCE TEMOZOLOMIDE ALONE ON SURVIVAL IN PATIENTS WI… 8.59 855 171.00
RA 8: unlabeled WELLER M;BUTOWSKI N;TR… 2017 RINDOPEPIMUT WITH TEMOZOLOMIDE FOR PATIENTS WITH NEWLY DIAGNOSED, EGFRVIII-EXPRESSING GLIOBLASTOMA (ACT IV): A RANDOMISED,… 7.13 495 99.00
RA 8: unlabeled HERRLINGER U;TZARIDIS … 2019 LOMUSTINE-TEMOZOLOMIDE COMBINATION THERAPY VERSUS STANDARD TEMOZOLOMIDE THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLAST… 9.07 213 71.00
RA 8: unlabeled CHEN R;SMITH-COHN M;CO… 2017 GLIOMA SUBCLASSIFICATIONS AND THEIR CLINICAL SIGNIFICANCE 5.25 280 56.00
RA 8: unlabeled TOUAT M;IDBAIH A;SANSO… 2017 GLIOBLASTOMA TARGETED THERAPY: UPDATED APPROACHES FROM RECENT BIOLOGICAL INSIGHTS 5.97 226 45.20
RA 8: unlabeled VAN DEN BENT MJ;BAUMER… 2017 INTERIM RESULTS FROM THE CATNON TRIAL (EORTC STUDY 26053-22054) OF TREATMENT WITH CONCURRENT AND ADJUVANT TEMOZOLOMIDE FOR… 5.18 204 40.80
RA 8: unlabeled DANG L;YEN K;ATTAR EC 2016 IDH MUTATIONS IN CANCER AND PROGRESS TOWARD DEVELOPMENT OF TARGETED THERAPEUTICS 3.41 270 45.00
RA 8: unlabeled QAZI MA;VORA P;VENUGOP… 2017 INTRATUMORAL HETEROGENEITY: PATHWAYS TO TREATMENT RESISTANCE AND RELAPSE IN HUMAN GLIOBLASTOMA 5.27 163 32.60
RA 8: unlabeled KICKINGEREDER P;NEUBER… 2018 RADIOMIC SUBTYPING IMPROVES DISEASE STRATIFICATION BEYOND KEY MOLECULAR, CLINICAL, AND STANDARD IMAGING CHARACTERISTICS IN… 7.02 111 27.75
RA 8: unlabeled AOKI K;NAKAMURA H;SUZU… 2018 PROGNOSTIC RELEVANCE OF GENETIC ALTERATIONS IN DIFFUSE LOWER-GRADE GLIOMAS 5.58 130 32.50
Research Area 9: RA 9: unlabeled (n = 301, density =0.64)
RA 9: unlabeled WANG J;CAZZATO E;LADEW… 2016 CLONAL EVOLUTION OF GLIOBLASTOMA UNDER THERAPY 5.68 380 63.33
RA 9: unlabeled FLAVAHAN WA;DRIER Y;LI… 2016 INSULATOR DYSFUNCTION AND ONCOGENE ACTIVATION IN IDH MUTANT GLIOMAS 2.79 700 116.67
RA 9: unlabeled LAN X;JÖRG DJ;CAVALLI … 2017 FATE MAPPING OF HUMAN GLIOBLASTOMA REVEALS AN INVARIANT STEM CELL HIERARCHY 5.52 191 38.20
RA 9: unlabeled CAPPER D;JONES DTW;SIL… 2018 DNA METHYLATION-BASED CLASSIFICATION OF CENTRAL NERVOUS SYSTEM TUMOURS 1.06 976 244.00
RA 9: unlabeled ZHAO J;CHEN AX;GARTREL… 2019 IMMUNE AND GENOMIC CORRELATES OF RESPONSE TO ANTI-PD-1 IMMUNOTHERAPY IN GLIOBLASTOMA 2.98 323 107.67
RA 9: unlabeled BARTHEL FP;JOHNSON KC;… 2019 LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS 6.60 136 45.33
RA 9: unlabeled REIFENBERGER G;WIRSCHI… 2017 ADVANCES IN THE MOLECULAR GENETICS OF GLIOMAS-IMPLICATIONS FOR CLASSIFICATION AND THERAPY 2.69 323 64.60
RA 9: unlabeled BEN-DAVID U;SIRANOSIAN… 2018 GENETIC AND TRANSCRIPTIONAL EVOLUTION ALTERS CANCER CELL LINE DRUG RESPONSE 2.12 366 91.50
RA 9: unlabeled MILLER AM;SHAH RH;PENT… 2019 TRACKING TUMOUR EVOLUTION IN GLIOMA THROUGH LIQUID BIOPSIES OF CEREBROSPINAL FLUID 3.69 205 68.33
RA 9: unlabeled OSUKA S;VAN MEIR EG 2017 OVERCOMING THERAPEUTIC RESISTANCE IN GLIOBLASTOMA: THE WAY FORWARD 3.14 229 45.80

Development

Connectivity between the research areas

Technical description

In a bibliographic coupling network, the coupling-strength between publications is determined by the number of commonly cited references they share, assuming a common pool of references to indicate similarity in context, methods, or theory. Formally, the strength of the relationship between a publication pair \(i\) and \(j\) (\(s_{i,j}^{bib}\)) is expressed by the number of commonly cited references.

\[s_{i,j}^{bib} = \sum_m c_{i,m} c_{j,m}\]

Since our corpus contains publications which differ strongly in terms of the number of cited references, we normalize the coupling strength by the Jaccard similarity coefficient. Here, we weight the intercept of two publications’ bibliography (shared refeences) by their union (number of all references cited by either \(i\) or \(j\)). It is bounded between zero and one, where one indicates the two publications to have an identical bibliography, and zero that they do not share any cited reference. Thereby, we prevent publications from having high coupling strength due to a large bibliography (e.g., literature surveys).

\[S_{i,j}^{jac-bib} =\frac{C(i \cap j)}{C(i \cup j)} = \frac{s_{i,j}^{bib}}{c_i + c_j - s_{i,j}^{bib}}\]

More recent articles have a higher pool of possible references to co-cite to, hence they are more likely to be coupled. Consequently, bibliographic coupling represents a forward looking measure, and the method of choice to identify the current knowledge frontier at the point of analysis.

Knowledge Bases, Research Areas & Topics Interaction

Endnotes

All results are preliminary so far…